Filter
1239
Filtered Results: 1239
Text search:
U.S.
Food
and
Drug
Administration
Featured
Recommendations
118
New Publications
352
Language
Document type
No document type
744
Guidelines
181
Studies & Reports
180
Manuals
60
Strategic & Response Plan
35
Fact sheets
14
Training Material
12
Situation Updates
6
Brochures
2
Resource Platforms
2
Videos
2
Infographics
1
Countries / Regions
India
62
Kenya
38
Global
38
Ethiopia
37
Nigeria
32
Uganda
28
Tanzania
28
South Africa
27
Sierra Leone
25
Liberia
25
Western and Central Europe
24
Philippines
22
Myanmar / Burma
21
Rwanda
19
Zambia
18
Ghana
15
USA
13
Latin America and the Carribbean
12
Nepal
11
Cambodia
11
Indonesia
11
Bangladesh
11
Africa
10
South Sudan
9
Malawi
9
Lesotho
9
Eastern Europe
9
Russia
9
Congo, Democratic Republic of
8
Botswana
8
Zimbabwe
7
Germany
7
Namibia
7
Ukraine
7
Colombia
7
West and Central Africa
7
Middle East and North Africa
6
Haiti
5
Syria
5
Mozambique
5
Brazil
5
Eastern Europe and Central Asia
5
Cameroon
4
Thailand
4
Sudan
4
Eswatini/ Swaziland
4
East and Southern Africa
4
South–East Asia Region
4
Laos
4
Jordan
3
Argentina
3
Peru
3
Paraguay
3
Venezuela
3
Senegal
2
Somalia
2
Iraq
2
Central African Republic
2
Angola
2
Sri Lanka
2
Western Pacific Region
2
Asia
2
Tajikistan
2
Vietnam
2
Guinea
1
Mali
1
Guinea-Bissau
1
Pakistan
1
Afghanistan
1
Turkey
1
Singapore
1
Papua New Guinea
1
Benin
1
Switzerland
1
El Salvador
1
Libya
1
Mexico
1
Yemen
1
Palestine
1
Qatar
1
Lithuania
1
Iran
1
Turkmenistan
1
Denmark
1
France
1
United Kingdom
1
Portugal
1
Spain
1
Authors & Publishers
Publication Years
Category
Countries
491
Clinical Guidelines
135
Public Health
60
Women & Child Health
39
Key Resources
28
Pharmacy & Technologies
18
Capacity Building
12
Toolboxes
Mental Health
107
TB
92
AMR
89
HIV
88
COVID-19
86
Pharmacy
60
Rapid Response
34
Ebola
33
NTDs
30
Caregiver
28
NCDs
26
Planetary Health
23
Refugee
18
Conflict
13
Specific Hazards
13
Disability
11
Zika
8
Global Health Education
8
Cholera
6
Natural Hazards
6
Polio
4
Social Ethics
4
Health Financing Toolbox
3
Health Financing
1
Options for the decontamination and reuse of respirators in the context of the COVID-19 pandemic
recommended
Guiding principles for reuse are:
Respirators which have been visibly contaminated (e.g. during procedure at intubated patients, such as suction cleaning of airways, taking probes, extubation attempts, etc.) or are damaged or not fitting, should be discarded ... cannot be taken for re-use or decontamination procedures.
Respirators may be protected by a medical face mask in order to prevent soiling.
Use of new ‘expired respirators’ (manufacturers expiry date) is possible if they were properly stored until use.
Sepsis remains a leading cause of mortality and morbidity, especially during the first five days of life and in low and middle-income countries (LM...
Taking the whole of Africa approach to fighting the COVID-19 pandemic has and will continue to require coordinated efforts from multiple stakeholders from across the continent. Africa CDC would like to acknowledge the deep partnership ... continued support of AUDA-NEPAD, AVAREF, WHO AFRO, the Bill and Melinda Gates Foundation and the Mastercard Foundation. These partners have helped to shape and drive the continent’s strategic response to the COVID-19 pandemic and have offered support to ensure the continent receives a fair and equitable share of the COVID-19 vaccine without delay.
We look forward to continuing and deepening our partnership for the benefit of the public health of Africa.
This document aims to provide interim guidance for microbiology and virology experts, other laboratory professionals, laboratory managers, infectious disease programme managers, public health professionals ... other stakeholders that provide primary, confirmatory or advanced testing for SARS-CoV-2, including genomic sequencing, or are involved in making decisions on establishing or scaling up capability and capacity to detect and characterize circulating SARS-CoV-2 variants.
Since 2000, concerted efforts by national programmes, supported by public–private partnerships, nongovernmental organizations, donors and academia under the auspices and coordination of the World ...
Access to NCD medicines: emergent issues during the COVID-19 pandemic and key structural factors
recommended
The coronavirus disease (COVID-19) pandemic exacerbated pre-existing inequalities in the treatment and care of noncommunicable diseases (NCDs). This report examines the effect of the COVID-19 pandemic on access to NCD medicines, ... the policies and strategies implemented by countries and health systems to anticipate and mitigate stresses across NCD medicine supply chains. The full range of upstream and downstream impacts are investigated, including: manufacturing; procurement, importation and last mile delivery; patient-level effects through affordability and availability; and the effects on NCD medicine availability by category of disease. The report culminates in recommended actions and interventions for key stakeholders in the NCD pharmaceutical supply chain, including governments, regulatory authorities, manufacturers and the private sector; as well as directions for future research for improving access and supply chain access resilience.
The coronavirus disease (COVID-19) pandemic exacerbated pre-existing inequalities in the treatment and care of noncommunicable diseases (NCDs). This report examines the effect of the COVID-19 pandemic on access to NCD medicines, ... the policies and strategies implemented by countries and health systems to anticipate and mitigate stresses across NCD medicine supply chains. The full range of upstream and downstream impacts are investigated, including: manufacturing; procurement, importation and last mile delivery; patient-level effects through affordability and availability; and the effects on NCD medicine availability by category of disease. The report culminates in recommended actions and interventions for key stakeholders in the NCD pharmaceutical supply chain, including governments, regulatory authorities, manufacturers and the private sector; as well as directions for future research for improving access and supply chain access resilience.
Interim rapid response guidance, 10 June 2022.
It includes considerations for certain populations such as patients with mild disease with considerations for community care, patients with moderate to severe disease, sexually active persons, pregnant or breastfeeding women, children ... young persons. The guidance also addresses considerations for clinical management such as the use of therapeutics, nutritional support, mental health services, and post-infection follow-up.
The document provides guidance for clinicians, health facility managers, health workers and infection prevention and control practitioners including but not limited to those working in primary care clinics, sexual health clinics, emergency departments, infectious diseases clinics, genitourinary clinics, dermatology clinics, maternity services, paediatrics, obstetrics and gynaecology and acute care facilities that provide care for patients with suspected or confirmed monkeypox
5th edition.
This technical package represents a select group of strategies based on the best available evidence to help communities and states sharpen their focus on prevention activities with the greatest potential to prevent suicide
Overcoming barriers in low- and middle-income countries
For the first time, this year’s report includes information on hepatitis C diagnostics. With a focus on selected countries with diverse HCV...
As part of the Mental Health Gap Action Programme, WHO has developed training manuals (Training of trainers and supervisors training manual and Training of health-care providers training manual) to ...
13 May 2021
To avoid a reversal of progress from the adverse impacts of the COVID-19 pandemic, new knowledge and lessons from successful programmatic innovations are urgently needed to improve TB prevention ... care. Experience can provide evidence for innovative approaches and strategies to maintain and scale up high-quality TB services. WHO therefore called for case studies on programmatic innovations that address emerging challenges in TB prevention and care during the pandemic in order to collect and disseminate the findings to the TB community. Between November 2020 and February 2021, a total of 23 case studies relevant to the call were accepted from 19 countries in the six regions of WHO. The lessons learnt from these country activities to ensure the continuity of essential services like TB care in the face of the crippling crisis may also inform strategies for minimizing the impact of future emerging pathogens on health services.
COVID-19 outbreak is associated with the generation of many types of infectious wastes, including infected masks, gloves and other protective equipment, together with a higher volume of general waste of the same nature.
